Get started

Community ideas

Reliance Inds cmp 1267.60 by Weekly Chart viewReliance Inds cmp 1267.60 by Weekly Chart view - Stock has formed Bearish Rounding Bottom - Support Zone seen at 1050 to 1100 Price Band - Support Zone 1250 to 1300 Price Band turning into Resistance Zone - Stock might probably show more downside by the Technical Chart setup - Weekly Basis : Support at 1195 > 1100 > 995 with Resistance at 1360 > 1445 >1535 > ATH 1608.80 - Stock Price gone well below the crossover of both the Falling Resistance Trendline and also the Rising Support Trendline been broken down
Editors' picks
NSE:RELIANCE
by PIYUSHCHAVDA
3
DCAL - Potential C&H -Back in Profits. Buy above 215.DCAL is forming Cup & Handle Pattern. One can enter above 215 with target of 255/400/600/780, with Stop Loss of 171. Here's a summary of the key points for investors from Dishman Carbogen Amcis Limited's (DCAL) presentation for Q2 FY25: Financial Highlights 1. Revenue Growth: Net revenue for Q2 FY25 increased by 34.5% YoY to ₹7,890 million, driven by a boost in commercial sales, particularly in the CRAMS (Contract Research and Manufacturing Services) segment in Switzerland and India. 2. Profitability: EBITDA rose significantly to ₹1,485 million with a margin increase from 10.8% in Q2 FY24 to 18.8% in Q2 FY25, due to higher volumes and improved operating margins. 3. Cash Profit: Cash profit for Q2 FY25 stood at ₹1,055 million, almost doubling YoY. 4. Net Debt: The company reported a net debt of CHF 173 million as of September 2024. 5. Capex: H1 FY25 capital expenditure reached approximately USD 15.9 million. Operational Highlights 1. Revenue Mix: - CRAMS: Major contributor with 84% of total revenue. Sales grew 51.7% YoY, fueled by increased commercial sales. - NCE APIs & Intermediates: 6.2% share, with a 36.9% increase in revenue due to growth at the Bavla site in India. - Cholesterol & Vitamin D Analogues: Decline in sales by 35.7% due to lower margin realization in Cholesterol SF. - Quats & Generics: Decline due to reduced demand in the agrochemical sector. 2. Capacity Utilization: Focused on improving capacity utilization by targeting small to mid-sized global biotech companies and expanding in new geographies. Strategic Insights 1. Global Presence: Operations span Switzerland, the UK, France, Netherlands, India, and China, with 28 R&D labs and multi-purpose facilities. 2. Oncology Focus: Oncology, a high-growth therapeutic area, is a priority, with several late-phase oncology molecules in the pipeline. 3. HIPO Facility: The Bavla site in India houses Asia's largest high-potency API (HIPO) facility, positioning DCAL well for growth in oncology. Industry Overview - Specialty Medicines Growth: Specialty medicines, which include high-potency oncology drugs, are projected to grow significantly, with an expected 43% share in global pharma spending by 2028. - Oncology Market: Oncology is projected to grow at a CAGR of 14-17% through 2028, driven by new treatments and demand for potent drugs. Investment Considerations 2. ⁠1. Strong Revenue and Margin Growth: Consistent revenue growth with enhanced EBITDA margins, indicating improved operational efficiency. 2. Global Expansion & Diversification: Expanding into new geographies and targeting small/mid-size biotech clients mitigates risk and enhances revenue stability. 3. Oncology Focus and HIPO Facility: The HIPO capabilities in India align with the high-growth oncology sector, suggesting long-term growth potential in specialty pharma.
Editors' picks
NSE:DCALLong
by jain_geetesh
1
A Healthcare Face-Off: Apollo vs. Narayana◉ Abstract India's hospital industry is growing rapidly, valued at ₹8.35 lakh cr. ($98.98 B) in 2023, with a projected CAGR of 5.8-8.0% from 2024 to 2032. Apollo Hospitals and Narayana Hrudayalaya are two leading players, with Apollo being the largest private hospital network and Narayana Hrudayalaya known for cost-effective cardiac care. Narayana Hrudayalaya appears undervalued with a P/E ratio of 33.5 and more profitable (ROCE: 27%), making it an attractive investment option. Apollo Hospitals seems overvalued with a P/E ratio of 83.4 but remains viable for strategic entry points. Both companies are poised for growth driven by increasing healthcare demands and infrastructure expansion. Read full analysis here........ ◉ Introduction The hospital industry in India is experiencing significant growth, with the market valued at approximately ₹8.35 lakh cr. ($98.98 B) in 2023. Projections indicate a robust compound annual growth rate (CAGR) of 5.8% to 8.0% from 2024 to 2032, potentially reaching between 13.87 lakh cr. and 16.33 lakh cr. ($164.4 B - $193.6 B) by 2032, depending on various market analyses. ◉ Growth Drivers of the Indian Hospital Industry ● Increased Healthcare Expenditure: ➖ Rising public and private spending on healthcare, with government health expenditure aiming for 2.5% of GDP by 2025. ➖ Expanding middle class with higher disposable incomes and greater access to health insurance. ● Technological Advancements: ➖ Adoption of healthcare technologies such as telemedicine and robotic automation, improving service delivery. ➖ National Digital Health Blueprint promoting innovations in e-health. ● Policy Support and Foreign Investment: ➖ Favourable government policies allowing 100% FDI in healthcare, attracting significant investments. ➖ Public-private partnerships enhancing healthcare access, especially in underserved areas. ● Demand for Specialized Services: ➖ Increasing incidence of lifestyle diseases driving demand for specialized healthcare. ➖ Growth in medical tourism as India becomes a preferred destination for cost-effective treatments. These factors are collectively propelling the growth of the hospital industry in India, positioning it for a promising future. ◉ Key players in the Indian hospital sector 1. Apollo Hospitals leads the sector with a market capitalization of approximately ₹98,646 Cr, establishing itself as the largest private hospital network in India. 2. Max Healthcare closely follows, boasting a market capitalization of around ₹97,820 Cr. 3. Fortis Healthcare is another key participant in the market, with a market capitalization of ₹48,249 Cr. 4. Global Health also ranks among the premier healthcare institutions, holding a market capitalization of ₹28,786 Cr. 5. Narayana Hrudayalaya is recognized for its cost-effective cardiac care services and maintains a notable market share with a market capitalization of ₹26,086 Cr. In this report, we will conduct an in-depth analysis and comparison between two of India's leading healthcare providers, Apollo Hospitals and Narayana Hrudayalaya. This comprehensive evaluation will assess their technical and fundamental aspects, ◉ Company Overviews ● Apollo Hospital NSE:APOLLOHOSP Apollo Hospitals was founded in 1983 by Dr. Prathap C Reddy, a visionary in the evolution of modern healthcare in India. As the first corporate hospital in the country, Apollo Hospitals is celebrated for leading the charge in the private healthcare transformation. Today, Apollo Hospitals stands as Asia's leading integrated healthcare services provider, boasting a strong footprint throughout the healthcare landscape. This includes a diverse range of services such as hospitals, pharmacies, primary care and diagnostic clinics, as well as various retail health models. ● Narayana Hrudalaya NSE:NH Narayana Hrudayalaya Limited is involved in providing medical and healthcare services both in India and abroad. It functions through two main divisions: Medical and Healthcare Related Services, and Others. The organization is responsible for acquiring, owning, and managing a variety of healthcare facilities, including hospitals, clinics, health centres, diagnostic centres, and nursing homes, among other related operations. Its range of services encompasses cardiology, cardiac surgery, nephrology, urology, neurology, neurosurgery, endocrinology, orthopaedics, internal medicine, obstetrics, gynaecology, pediatrics, neonatology, gastroenterology, and oncology. Additionally, the company is active in the health insurance sector. Established in 2000, its headquarters is located in Bengaluru, India. ◉ Technical Analysis ● Apollo Hospitals ➖ The stock faced a significant obstacle near the 5,800 level, resulted in a steep drop. ➖ It later found support around 3,500 and rebounded. ➖ Following an extended period of consolidation, the price developed a Rounding Bottom pattern. ➖ A breakout ensued, leading to a price increase, but it encountered resistance close to 6,800, which triggered a pullback to the breakout point. ➖ Following a successful retest, the price surged past the previous high, reaching a new peak at 7,545. ➖ However, due to prevailing negative market sentiments, the price has since retraced and is currently trading just above its immediate support zone. ● Narayana Hrudalaya ➖ The stock price is overall in an uptrend. ➖ After reaching an all-time high close to the 1,445 level, the price experienced a decline and has since entered a consolidation phase. ➖ A Symmetrical Triangle pattern has formed on the chart. ➖ We expect an upward breakout from this pattern, which could lead to a significant price rally. ◉ Relative Strength ➖ The chart reveals that both Apollo and Narayana Hrudayalaya have underperformed the Nifty Healthcare index. Although Apollo has given a descent 31% return, Narayana lagged significantly, yielding a modest 17% return. In contrast, the Nifty Healthcare index delivered an impressive 41% return. ◉ Service Wise Revenue Breakdown ● Apollo Hospitals The company operates through three primary segments, each contributing significantly to its revenue. ➖ Healthcare services account for approximately 52% of total revenue, forming the largest share. ➖ The retail pharmacy business generates nearly 41% of total sales, while the retail health and diagnostics segment contributes the remaining 7%. ● Narayana Hrudalaya ➖ The company operates exclusively in the healthcare services sector, deriving all its revenue from this single segment. ◉ Revenue & Profit Analysis ● Apollo Hospitals Year-over-Year ➖ The company's fiscal year 2024 performance was marked by strong growth, with revenue reaching ₹19,059 crore, a 15% increase from ₹16,612 crore in FY23. ➖ EBITDA surged to ₹2,394 crore, up from ₹2,065 crore in FY23, while the EBITDA margin improved to 13% from 12%. Quarter-over-Quarter ➖ In the latest quarter ending September 2024, the company achieved its highest-ever sales of ₹5,589 crore, significantly up from ₹5,086 crore in June 2024. This quarter-on-quarter growth has been consistent since March 2022. ➖ EBITDA for the quarter was an impressive ₹816 crore, a 21% increase from ₹675 crore in June 2024. ➖ Diluted EPS (LTM) rose substantially to ₹83.31 from ₹72.13 in June 2024. ● Narayana Hrudalaya Year-over-Year ➖ In FY24, our company achieved remarkable sales growth, surging 11% to ₹5,018 crore from ₹4,525 crore in FY23. ➖ EBITDA soared to ₹1,173 crore, up from ₹987 crore in the same period, with an impressive EBITDA margin of 23%. Quarter-over-Quarter ➖ Our quarterly sales reached an all-time high of ₹1,400 crore in September, representing a 4% increase from ₹1,341 crore in June. ➖ Although EBITDA growth was modest, it still improved to ₹308 crore in September from ₹304 crore in June 2024. ➖ However, Diluted EPS experienced a decline, dropping to ₹38.85 from ₹39.72. ◉ Valuation ● P/E Ratio ➖ Apollo Hospitals' current P/E ratio stands at 83.4, down from its 1-year median of 107.7. However, this remains significantly above the industry average of 56.9, indicating overvaluation. ➖ In contrast, Narayana Hrudalaya's P/E ratio of 33.5 is slightly above its 1-year median of 32.8 and substantially below the industry average, suggesting undervaluation. ● P/B Ratio ➖ Apollo's P/B ratio of 13.15 indicates considerable overvaluation compared to the industry average of 7.18. ➖ Narayana Hrudalaya's P/B ratio of 8.14 also suggests overvaluation, albeit to a lesser extent. ● PEG Ratio ➖ Narayana's PEG ratio of 0.49 positions it as an attractive investment opportunity, especially when compared to Apollo's considerably higher PEG of 2.43. ◉ Profitability Analysis ➖ Apollo Hospitals ROCE - 15% in FY24 ➖ Narayana Hrudalaya ROCE - 27% in FY24 The significant difference in ROCE between the two healthcare giants underscores Narayana Hrudalaya's superior profitability. Narayana's impressive ROCE of 27% demonstrates its ability to efficiently utilize its total capital, comprising both equity and debt, to generate substantially higher returns. ◉ Cash Flow Analysis ➖ Apollo Hospitals has demonstrated impressive growth in its operating cash flow, surging 39% to ₹1,920 crore in FY24 from ₹1,377 crore in FY23. This robust growth underscores the company's efficiency in converting profits into cash, highlighting its strong financial health and liquidity position. ➖ In contrast, Narayana Hrudalaya has shown sluggishness in turning profits into cash, with its operating cash flow declining 2% to ₹1,067 crore in FY24 from ₹1,085 crore in FY23. ◉ Debt Analysis ➖ Apollo Hospitals' debt stands at ₹7,371 crore, resulting in a debt-to-equity ratio of 0.98, which, although relatively high, is not alarming. However, the company's low interest coverage ratio of 4.69 raises concerns about its ability to service its debt. This vulnerability may complicate repayment of borrowed loans, potentially straining Apollo's financial stability. ➖ In contrast, Narayana Hrudalaya's debt of ₹1,703 crore and debt-to-equity ratio of 0.53 indicate robust financial health. Furthermore, its impressive interest coverage ratio of 8.34 suggests the company is well-positioned to manage its debt obligations, ensuring greater financial flexibility and stability. ◉ Shareholding Pattern ● Apollo Hospitals ➖ In the September quarter, Foreign Institutional Investors (FIIs) increased their stake in Apollo Hospitals to 45.37%, up from the previous quarter. ➖ Conversely, Domestic Institutional Investors (DIIs) reduced their holdings to 19.94%, a significant decrease from 24.77% in the last quarter. ● Narayana Hrudalaya ➖ In contrast, Narayana Hrudalaya witnessed a decline in institutional investor holdings. FIIs reduced their stake to 9.69%, down from 10% in the previous quarter. ➖ Domestic Institutional Investors (DIIs) also decreased their holdings to 7.9%, down from 8.22% in the June quarter. ◉ Conclusion Following a comprehensive analysis of both technical and fundamental aspects, we conclude that Narayana Hrudalaya appears to be favorably positioned from a valuation perspective, presenting an attractive investment opportunity. However, this does not diminish Apollo Hospitals' potential. Although the stock currently appears overvalued, investors can consider accumulating shares during dips, making it a viable option for those seeking strategic entry points. The healthcare sector's promising growth trajectory, fueled by rising healthcare demands and infrastructure expansion, positions both companies for potentially excellent returns in the near future.
NSE:APOLLOHOSPLong
by GoodluckCapital
1
EUR/USD Slips Amid Strong Downward MomentumThe current downtrend in the EUR/USD pair is evident, with the price testing a critical support level around 1.0550. Over the past few months, EUR/USD has consistently depreciated, largely driven by the strengthening of the USD and unfavorable factors for the Euro. This support level has previously acted as a From a technical perspective, if this support zone fails to hold, the price is likely to continue its decline towards the next level around 1.0311, according to Fibonacci levels. This is a strong psychological level that could further pressure investors looking to maintain long positions. Signals from the moving averages also confirm the bearish trend, as these lines are aligned above the price, reinforcing the negative outlook.
Editors' picks
Short
by Mr_Siro
2
Nifty View Bounce and Break !Hello mates sharing a view on Nifty on daily time frame, So as we can see that after a good correction form all time highs now price reached to 200 Ema so let's discuss what are the probabilities we can see from here. Current View-: So it look like that price is taking support from 200 Ema as in yesterday's session price breached that but did not close below so we can expecet a bounce towards 24000 to 24500 then again price will make a lower high there and after came down for cracking that 200 Ema. Alternative view-: That Price will break 200 Ema directly from here as overall sentiments also seems not good and in favour of defend this moving average. if moving average will break then we can see a rally towards marked support zone below. I will try my best to update this publication for a bounce or a break too stay tuned. Hope you like my idea, Thanks in advance. Best regards- Amit
NSE:NIFTY
by AMIT-RAJAN
9
BUY TODAY SELL TOMORROW for 5%DON’T HAVE TIME TO MANAGE YOUR TRADES? - Take BTST trades at 3:25 pm every day - Try to exit by taking 4-7% profit of each trade - SL can also be maintained as closing below the low of the breakout candle Now, why do I prefer BTST over swing trades? The primary reason is that I have observed that 90% of the stocks give most of the movement in just 1-2 days and the rest of the time they either consolidate or fall Consolidation Breakout in KIRIINDUS BUY TODAY SELL TOMORROW for 5%
NSE:KIRIINDUS
by Kapil-Mittal
2
Update latest gold price today !Hello everyone! Gold has been in a steady decline since the start of the week, currently sitting at 2561, with strong indications that this downtrend may persist. The key 2550 level is still fiercely contested, keeping traders on edge. The market remains clouded with apprehension, especially with recent developments in the U.S. following Donald Trump's election as president. This lingering uncertainty may continue to weigh heavily on gold. At the moment, all attention is focused on the upcoming October Producer Price Index (PPI) report in the U.S. Analysts are forecasting a year-over-year increase of 2.3% for October, a notable jump from September's 1.8%. If both the CPI and PPI show further inflationary pressure, the Federal Reserve could be pushed to raise interest rates, which could apply even more pressure on gold prices. A stronger U.S. dollar would make gold trading and holding costs more expensive, potentially intensifying the sell-off. Technically speaking, the battle at 2550 is far from over, and there’s a strong likelihood of a brief pullback before continuing the downward trend. This could mean a possible retest of the 2600-2580 resistance zone before resuming its decline. Chart patterns suggest that if the correction unfolds as anticipated—possibly in line with an Elliott wave impulse—the target could be around 2485, a drop of over 1000 pips from the resistance level. Stay tuned for more developments as this situation unfolds!
OANDA:XAUUSDShort
by Bo-Samson
1
Zomato Ltd (NSE: ZOMA Technical Analysis and Potential Trad Zomato is showing a breakout from a descending channel on the daily chart, signaling a potential bullish trend reversal. The stock has risen above the resistance level, with strong buying momentum indicated by recent volume spikes. Key Observations: Fibonacci Levels: The price has surpassed the 0.618 Fibonacci retracement level, suggesting further upside potential. Key levels to watch are the 1 level at ₹240 (support) and the current level around ₹269, with possible resistance near ₹284. Indicators: MACD: Positive crossover with rising histogram bars, indicating bullish momentum. RSI: RSI is trending upwards and is above 57, suggesting increased buying interest without being overbought. Volume: Volume spike confirms the breakout from the channel. Trade Idea: If the stock sustains above ₹269, it may continue to rise, with immediate resistance around ₹284. A sustained close above this level could confirm the uptrend. Stop-loss can be considered near ₹254.83 (recent support). Disclaimer: This analysis is provided for educational purposes only and should not be considered as financial advice. All trading involves risk, and you should conduct your own research before making any investment decisions. I am not a licensed financial advisor, and this idea reflects only my personal opinion and analysis based on publicly available information.
NSE:ZOMATOLong
by Falcon_Insights
Zomato Ltd (NSE: ZOMA Technical Analysis and Potential Trad Zomato is showing a breakout from a descending channel on the daily chart, signaling a potential bullish trend reversal. The stock has risen above the resistance level, with strong buying momentum indicated by recent volume spikes. Key Observations: Fibonacci Levels: The price has surpassed the 0.618 Fibonacci retracement level, suggesting further upside potential. Key levels to watch are the 1 level at ₹240 (support) and the current level around ₹269, with possible resistance near ₹284. Indicators: MACD: Positive crossover with rising histogram bars, indicating bullish momentum. RSI: RSI is trending upwards and is above 57, suggesting increased buying interest without being overbought. Volume: Volume spike confirms the breakout from the channel. Trade Idea: If the stock sustains above ₹269, it may continue to rise, with immediate resistance around ₹284. A sustained close above this level could confirm the uptrend. Stop-loss can be considered near ₹254.83 (recent support). Disclaimer: This analysis is provided for educational purposes only and should not be considered as financial advice. All trading involves risk, and you should conduct your own research before making any investment decisions. I am not a licensed financial advisor, and this idea reflects only my personal opinion and analysis based on publicly available information.
NSE:ZOMATOLong
by Falcon_Insights